Search Results - "Thuluvath, P.J"

Liver Transplantation in the United States, 1999–2008 by Thuluvath, P. J., Guidinger, M. K., Fung, J. J., Johnson, L. B., Rayhill, S. C., Pelletier, S. J.

“…Changes in organ allocation policy in 2002 reduced the number of adult patients on the liver transplant waiting list, changed the characteristics of transplant…”
Get full text

High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy and safety analysis of genotype 1–6 patients without cirrhosis by Puoti, M, Foster, G, Wang, S, Mutimer, D, Gane, E, Moreno, C, Chang, T.T, Lee, S.S, Marinho, R, Dufour, J.-F, Pol, S, Hezode, C, Gordon, S.C, Strasser, S.I, Thuluvath, P.J, Liu, R, Pilot-Matias, T, Mensa, F

Get full text

1423 INTERIM ANALYSIS OF AN INTERFERON (IFN)- AND RIBAVIRIN (RBV)-FREE REGIMEN OF DACLATASVIR (DCV), ASUNAPREVIR (ASV), AND BMS-791325 IN TREATMENT-NAIVE, HEPATITIS C VIRUS GENOTYPE 1-INFECTED PATIENTS by Everson, G.T, Sims, K.D, Rodriguez-Torres, M, H'ezode, C, Lawitz, E, Bourlière, M, Loustaud-Ratti, V, Rustgi, V, Schwartz, H, Tatum, H, Marcellin, P, Pol, S, Thuluvath, P.J, Eley, T, Wang, X, Huang, S.-P, McPhee, F, Wind-Rotolo, M, Chung, E, Pasquinelli, C, Grasela, D.M, Gardiner, D.F

Get full text

P1163 ALL-ORAL THERAPY WITH DACLATASVIR IN COMBINATION WITH ASUNAPREVIR AND BMS-791325 FOR TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE 4 INFECTION by Hassanein, T, Sims, K, Bennett, M, Gitlin, N, Lawitz, E, Nguyen, T, Webster, L, Younossi, Z, Schwartz, H, Thuluvath, P.J, Zhou, H, Rege, B, McPhee, F, Zhou, N, Wind-Rotolo, M, Chung, E, Griffies, A, Grasela, D, Gardiner, D.F

Get full text

1420 ASUNAPREVIR WITH PEGINTERFERON-ALFA AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE-1 OR -4 CHRONIC HEPATITIS C: SVR24 RESULTS FROM A RANDOMIZED PHASE 2B STUDY (AI447016) by Bronowicki, J.-P, Ratziu, V, Gadano, A, Thuluvath, P.J, Bessone, F, Martorell, C.T, Pol, S, Terg, R, Younes, Z, He, B, Eley, T, Cohen, D, Mendez, P, Hughes, E.A

Get full text

1417 SUSTAINED VIROLOGIC RESPONSE WITH DACLATASVIR PLUS SOFOSBUVIR ± RIBAVIRIN (RBV) IN CHRONIC HCV GENOTYPE (GT) 1-INFECTED PATIENTS WHO PREVIOUSLY FAILED TELAPREVIR (TVR) OR BOCEPREVIR (BOC) by Sulkowski, M.S, Gardiner, D.F, Rodriguez-Torres, M, Reddy, K.R, Hassanein, T, Jacobson, I, Lawitz, E, Lok, A.S, Hinestrosa, F, Thuluvath, P.J, Schwartz, H, Nelson, D.R, Everson, G.T, Eley, T, Wind-Rotolo, M, Huang, S.-P, Gao, M, McPhee, F, Hernandez, D, Sherman, D, Hindes, R, Symonds, W, Pasquinelli, C, Grasela, D.M

Get full text

1195 BMS-650032, AN NS3 INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION by Bronowicki, J.-P, Pol, S, Thuluvath, P.J, Larrey, D, Martorell, C.T, Rustgi, V.K, Morris, D.W, Younes, Z, Fried, M.W, Bourliere, M, Hezode, C, Massoud, O, Abrams, G.A, Ratziu, V, Thiry, A, Llamoso, C, Hughes, E.A, Hindes, R.G

Get full text

Liver transplantwaitlist mortality, transplantation rates and postliver transplant outcomes in Hispanics by Thuluvath, P.J., Savva, Y.

Get full text

FRI-027 - Incidence of waitlist removal and transplantation rates are similar in NASH, cryptogenic and autoimmune hepatitis cirrhosis by Thuluvath, P.J., Savva, Y.

Get full text

Incidence of waitlist removal and transplantation rates are similar in NASH, cryptogenic and autoimmune hepatitis cirrhosis by Thuluvath, P.J., Savva, Y.

Get full text

FRI-028 - Liver transplantwaitlist mortality, transplantation rates and postliver transplant outcomes in Hispanics by Thuluvath, P.J., Savva, Y.

Get full text

Liver transplantation in patients with multiple organ failures is feasible with good outcomes by Thuluvath, P.J., Thuluvath, A., Savva, Y.

Get full text

Number of organ failures is a better predictor of waitlist mortality in those who die within 30 days of listing for liver transplantation by Thuluvath, P.J., Thuluvath, A., Savva, Y.

Get full text

PS-042 - Liver transplantation in patients with multiple organ failures is feasible with good outcomes by Thuluvath, P.J., Thuluvath, A., Savva, Y.

Get full text

THU-247 - Number of organ failures is a better predictor of waitlist mortality in those who die within 30 days of listing for liver transplantation by Thuluvath, P.J., Thuluvath, A., Savva, Y.

Get full text

Natural history of autonomic neuropathy in chronic liver disease by Hendrickse, M T, Thuluvath, P J, Triger, D R

“…To determine the natural history of autonomic neuropathy in chronic liver disease we used standard cardiovascular autonomic tests to evaluate prospectively 60…”
Get more information

Phase II Study of the Efficacy and Safety of Cisplatin-Epinephrine Injectable Gel Administered to Patients With Unresectable Hepatocellular Carcinoma by LEUNG, T. W. T, YU, S, STEWART, M, ORENBERG, E. K, THULUVATH, P. J, JOHNSON, P. J, GESCHWIND, J, VOGL, T. J, ENGELMANN, K, GORES, G. J, GIOVANNINI, M, O'GRADY, J, HENEGHAN, M

“…To study the efficacy and safety of percutaneous cisplatin-epinephrine (CDDP-EPI) injectable gel in patients with localized unresectable hepatocellular…”
Get full text

Pretransplant Karnofsky Performance Status is an independent predictor of post-liver transplant survival by Thuluvath, P.J., Cherry, A., Thuluvath, A., Savva, Y.

Get full text

FRI-029 - Pretransplant Karnofsky Performance Status is an independent predictor of post-liver transplant survival by Thuluvath, P.J., Cherry, A., Thuluvath, A., Savva, Y.

Get full text

THU-225 - Primary biliary cholangitis (PBC) in the U.S.: clinical characteristics of patients enrolled in TARGET-PBC by Bowlus, C., Carey, E., Demuth, G., Deane, K., Mayo, M.J., Ray Kim, W., Bacon, B., Bernstein, D., Thuluvath, P.J., Michael Weiss, L., Fried, M.W.

Get full text